Asset Details
Do you wish to reserve the book?
Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia
Do you wish to request the book?
Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia
2024
Overview
Background
Chronic myeloid leukaemia (CML) is a type of blood cancer that begins in the hematopoietic stem cells. It is primarily characterized by a specific chromosomal aberration, the Philadelphia chromosome. While the fusion gene is a major contributor to CML, several other genes including ADGRE2, that are reported as highly expressed in hematopoietic stem cells and could be utilized as a therapeutic marker in leukemic patients are implicated in the disease’s progression. Until recently, little research had been conducted to identify single nucleotide polymorphisms (SNPs) associated with CML. Therefore, this study aims to investigate the influence of non-synonymous variants on the structure and function of the gene encoding adhesion G protein-coupled receptor E2, ADGRE2, and to evaluate their association with CML and its clinical and pathological characteristics.
Methods
Non-synonymous SNPs of ADGRE2 were retrieved from the ENSEMBL, COSMIC, and gnomAD genome browsers, and the pathogenicity of deleterious variants was assessed using several established computational tools, including SIFT, CADD, REVEL, PolyPhen, and MetaLR.
Results
Various in silico analyses explored the impact of damaging SNP on the function, stability, and structure of EGF-like modules containing mucin-like hormone receptor-like2 (EMR2) protein encoded by the ADGRE2 gene. Genotype analysis was performed on collected blood samples, revealing that altered genotype TT of variant rs765071211 (C/T) was associated significantly with CML patients compared to the control. Further in vitro and in vivo analyses suggest that this SNP holds potential for clinical translation.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Analysis
/ ARMS PCR
/ Biomedical and Life Sciences
/ CML
/ Disease
/ Female
/ Genes
/ Genetic Predisposition to Disease
/ Genomics
/ Health Promotion and Disease Prevention
/ Humans
/ Kinases
/ Leukemia
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
/ Male
/ Oncology
/ Patients
/ Polymorphism, Single Nucleotide
/ Proteins
/ Receptors, G-Protein-Coupled - genetics
/ Single nucleotide polymorphisms
/ Single-nucleotide polymorphism
